{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:46:08Z","timestamp":1777045568771,"version":"3.51.4"},"reference-count":28,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Southern African Journal of Infectious Diseases"],"DOI":"10.4102\/sajid.v38i1.522","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T07:32:59Z","timestamp":1690270379000},"source":"Crossref","is-referenced-by-count":4,"title":["Severe efavirenz associated neurotoxicity: A retrospective cohort study"],"prefix":"10.4102","volume":"38","author":[{"given":"Priyadarshini","family":"Arnab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Croxford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameshan","family":"Perumal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahraa","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2580","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"ref0","unstructured":"HIV\/AIDS JUNPo. UNAIDS South Africa. United Nations [homepage on the Internet]. 2018 [cited 2019 Oct 18]. Available from: http:\/\/www.unaids.org\/en\/regionscountries\/countries\/southafrica"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: Updated guidelines from the Centres for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(9):1308-1311. https:\/\/doi.org\/10.1093\/cid\/ciu094","DOI":"10.1093\/cid\/ciu094"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics. 2005;15(1):1-5. https:\/\/doi.org\/10.1097\/01213011-200501000-00001","DOI":"10.1097\/01213011-200501000-00001"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Kwara A, Lartey M, Sagoe K, Rzek N, Court M. CYP2B6 (c.516G\u2192T) and CYP2A6(4):427-436*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV infected patients. Br J Clin Pharmacol. 2009. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03368.x","DOI":"10.1111\/j.1365-2125.2009.03368.x"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Van Rensburg R, Nightingale S, Brey N, et al. Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome (LENS). Clin Infect Dis. 2022;75(3):399-405. https:\/\/doi.org\/10.1093\/cid\/ciab961","DOI":"10.1093\/cid\/ciab961"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Sonderup MW, Maughan D, Gogela N, et al. Identification of a novel and severe pattern of efavirenz drug-induced liver injury in South Africa. AIDS. 2016;30(9):1483-1485. https:\/\/doi.org\/10.1097\/QAD.0000000000001084","DOI":"10.1097\/QAD.0000000000001084"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV. Efavirenz and the CNS: What we already know and questions that need to be answered. J Antimicrob Chemother. 2015;70(10):2693-2708. https:\/\/doi.org\/10.1093\/jac\/dkv183","DOI":"10.1093\/jac\/dkv183"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Decloedt EH, Maartens G. Neuronal toxicity of efavirenz: A systematic review. Expert Opin Drug Saf. 2013;12(6):841-846. https:\/\/doi.org\/10.1517\/14740338.2013.823396","DOI":"10.1517\/14740338.2013.823396"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Dheda M. Efavirenz and neuropsychiatric effects. South Afr J HIV Med. 2017;18(1):741. https:\/\/doi.org\/10.4102\/sajhivmed.v18i1.741","DOI":"10.4102\/sajhivmed.v18i1.741"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hauptfleish MPK, Moore DPK. Efavirenz as a cause of ataxia in children. S Afr Med J. 2015;105(11), 897-898. https:\/\/doi.org\/10.7196\/SAMJ.2015.v105i11.9451","DOI":"10.7196\/SAMJ.2015.v105i11.9451"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Kenyon C, Mfolozi S, Croxford R, Colebunders R, Cohen K. Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia. Br J Clin Pharmacol. 012;74(6):1070-1072. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04299.x","DOI":"10.1111\/j.1365-2125.2012.04299.x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011;76(16), 1403-1409. https:\/\/doi.org\/10.1212\/WNL.0b013e31821670fb","DOI":"10.1212\/WNL.0b013e31821670fb"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Cross HM, Chetty S, Asukile MT, Hussey HS, Lee Pan EB, Tucker LM. A proposed management algorithm for late-onset management algorithm. S Afr Med J. 2018;108(4):271-274. https:\/\/doi.org\/10.7196\/SAMJ.2018.v108i4.12914","DOI":"10.7196\/SAMJ.2018.v108i4.12914"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Variava E, Sigauke FR, Norman J, et al. Late Efavirenz induced Ataxia and Encephalopathy. J Acquir Immune Defic Syndr. 2017;75(5):577-579. https:\/\/doi.org\/10.1097\/QAI.0000000000001451","DOI":"10.1097\/QAI.0000000000001451"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Ma Q, Vaida F, Wong J. Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol. 2016;22(2):170-178. https:\/\/doi.org\/10.1007\/s13365-015-0382-7","DOI":"10.1007\/s13365-015-0382-7"},{"key":"ref15","unstructured":"National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1; 2017 Jul."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Manosuthi W, Sungkanuparph S, Tantanathip P, et al. Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin. Antimicrob Agents Chemother. 2009;53(10):4545-4548. https:\/\/doi.org\/10.1128\/AAC.00492-09","DOI":"10.1128\/AAC.00492-09"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P. CYP2B6*6, CYP2B6*18, body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: Population pharmacokinetic-modeling in an HIV\/AIDS and TB cohort in Zimbabwe. BMC Pharmacol Toxicol. 2015;16:4. https:\/\/doi.org\/10.1186\/s40360-015-0004-2","DOI":"10.1186\/s40360-015-0004-2"},{"key":"ref18","unstructured":"National Department of Health (NDoH), Statistics South Africa (Stats SA), South African Medical Research Council (SAMRC), ICF. South Africa demographic and health survey 2016. Pretoria: NDoH, Stats SA, SAMRC, ICF; 2019."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Mangili A, Murman DH, Zampini AM, Wanke CA, Mayer KH. Nutrition and HIV infection: Review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis. 2006;42(6):836-842. https:\/\/doi.org\/10.1086\/500398","DOI":"10.1086\/500398"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Polo M, Algere F, Funes HA, et al. Mitochondrial (dys) function - A factor underlying the variability of efavirenz-induced hepatotoxicity? Br J Pharmacol. 2015;172(7):1713-1727. https:\/\/doi.org\/10.1111\/bph.13018","DOI":"10.1111\/bph.13018"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Nightingale S, Chau TTH, Fisher M, et al. Efavirenz and metabolites in cerebrospinal fluid: Relationship with CYP2B6 c.516G\u2192T Genotype and perturbed blood-brain barrier due to tuberculous meningitis. Antimicrob Agents Chemother. 2016;60(8):4511-4518. https:\/\/doi.org\/10.1128\/AAC.00280-16","DOI":"10.1128\/AAC.00280-16"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Yimer G, Ueda N, Habtewold A, et al. High plasma Efavirenz, slow NAT2 acetylators and ABCB1 genotype are associated with anti tubercular and Efavirenz based ARV drugs induced liver injury in TB-HIV patients. Trop Med Int Health. 2012;17:5-6. https:\/\/doi.org\/10.1371\/journal.pone.0027810","DOI":"10.1371\/journal.pone.0027810"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Zhang M, Wang S, Wilffert B, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: A systematic review and meta-analysis. Br J Clin Pharmacol. 2018;84(12):2747-2760. https:\/\/doi.org\/10.1111\/bcp.13722","DOI":"10.1111\/bcp.13722"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Mthiyane T, Millard J, Adamson J, et al. N-Acetyltransferase 2 genotypes among Zulu-speaking South Africans and Isoniazid and N-Acetyl-Isoniazid pharmacokinetics during antituberculosis treatment. Antimicrob Agents Chemother. 2020;64(4):e02376-19. https:\/\/doi.org\/10.1128\/AAC.02376-19","DOI":"10.1128\/AAC.02376-19"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Gausi K, Wiesner L, Norman J, et al. Pharmacokinetics and drug-drug interactions of Isoniazid and Efavirenz in pregnant women living with HIV in high TB incidence settings: Importance of genotyping. Clin Pharmacol Ther. 2021;109(4):1034-1044. https:\/\/doi.org\/10.1002\/cpt.2044","DOI":"10.1002\/cpt.2044"},{"key":"ref26","unstructured":"World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: Interim guidelines: Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2018."},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Walmsley S, Baumgarten A, Berenguer J. Brief report: Dolutegravir plus Abacavir\/Lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: Week 96 and Week 144 results from the SINGLE randomized clinical trial. J Acquir Immunodefic Syndr. 2015;70(5):515-519. https:\/\/doi.org\/10.1097\/QAI.0000000000000790","DOI":"10.1097\/QAI.0000000000000790"}],"container-title":["Southern African Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/522\/1242","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/522\/1243","content-type":"application\/epub+zip","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/522\/1244","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/522\/1245","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/viewFile\/522\/1245","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T11:43:39Z","timestamp":1744890219000},"score":1,"resource":{"primary":{"URL":"https:\/\/sajid.co.za\/index.php\/sajid\/article\/view\/522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,24]]}},"URL":"https:\/\/doi.org\/10.4102\/sajid.v38i1.522","relation":{},"ISSN":["2313-1810","2312-0053"],"issn-type":[{"value":"2313-1810","type":"electronic"},{"value":"2312-0053","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}